AMGN vs GILD: which stock is the better buy?
Amgen Inc. and Gilead Sciences, Inc., graded by the same fixed-weight model from live fundamentals — composite score, 12-month forecast, valuation, growth and margins, side by side. As of July 6, 2026.
On today’s numbers, Gilead Sciences, Inc. grades higher — 67/100 vs 64/100. Tap either card for the full factor breakdown.
Metric by metric
| Metric | AMGN | GILD |
|---|---|---|
| TradersQuant Score | 64/100 | 67/100 ✓ |
| Price | $374.15 | $131.27 |
| 12-mo base forecast | $480.16 | $195.11 |
| Implied upside | +28.3% | +48.6% ✓ |
| Bull / bear range | $530.67 / $459.96 | $213.72 / $188.56 |
| P/E | 25.8 | 17.7 ✓ |
| Forward P/E | — | — |
| Revenue growth (YoY) | +9.9% ✓ | +2.4% |
| Gross margin | 71.5% | 79.4% ✓ |
| Market cap | $201.9B | $163.0B |
| Sector | Healthcare | Healthcare |
✓ marks the stronger reading per metric (lower is better for P/E). Figures refresh continuously; research, not financial advice.
Want the full verdict on AMGN and GILD?
The AI bull/base/bear thesis, smart-money positioning, options signals and insider activity on both — every systematic call graded in public against the S&P 500.
$0 today · cancel before day 7 and you won’t be charged
AMGN vs GILD — FAQ (2026)
Is AMGN or GILD the better buy right now?
On the live TradersQuant composite score, Gilead Sciences, Inc. (GILD) currently grades higher at 67/100 versus 64/100 for AMGN. The score weighs valuation, growth, earnings quality, momentum, the macro regime, sentiment and balance-sheet risk — open each stock's page for the full breakdown. Research, not financial advice.
Which has more 12-month upside, AMGN or GILD?
TradersQuant's 12-month base-case forecast currently implies +28.3% for AMGN and +48.6% for GILD. Both forecasts are three-scenario models (bull/base/bear) refreshed continuously and graded on our public track record.
How is this AMGN vs GILD comparison calculated?
Both stocks are scored by the same fixed-weight model — 20% valuation, 20% growth, 15% earnings quality, 15% momentum, 10% macro regime fit, 10% analyst sentiment, 10% balance-sheet risk — from live fundamentals and prices. No hand-picking: the same arithmetic runs on every stock we cover, and our systematic calls are graded in public against the S&P 500.